Circassia Pharmaceuticals Plc FDA website posts Duaklir NDA approval (5475U)
March 29 2019 - 11:58AM
UK Regulatory
TIDMCIR
RNS Number : 5475U
Circassia Pharmaceuticals Plc
29 March 2019
Circassia Notes FDA Website Posting of Duaklir(R) in Approvals
Section
Oxford, UK - 29 March 2019: Circassia Pharmaceuticals plc
("Circassia" or "the Company"; LSE: CIR), notes the US Food and
Drug Administration (FDA) website includes Duaklir(R) as an FDA
approved drug product with an action date of 29 March 2019.
Circassia and AstraZeneca are seeking confirmation from FDA and
intend to update the market as soon as possible with further
details.
Contacts
Circassia
Steve Harris, Chief Executive Officer Tel: +44 (0) 1865 405
560
Julien Cotta, Chief Financial Officer
Rob Budge, Corporate Communications
Peel Hunt (Nominated Adviser and Joint Broker)
James Steel / Dr Christopher Golden Tel: +44 (0) 20 7418
8900
Numis Securities (Joint Broker)
James Black / Freddie Barnfield Tel: +44 (0) 20 7260 1000
FTI Consulting
Simon Conway / George Kendrick Tel: +44 (0) 20 3727 1000
About Circassia
Circassia is a world-class specialty pharmaceutical business
focused on respiratory disease. The Company sells its novel,
market-leading NIOX(R) asthma management products directly to
specialists in the United States, United Kingdom, China and
Germany, and in a wide range of other countries through its network
of partners. In the United States, Circassia has a commercial
collaboration with AstraZeneca in which it has the commercial
rights to chronic obstructive pulmonary disease (COPD) treatments
Tudorza(R) and Duaklir(R). Circassia also has the US and Chinese
commercial rights to the late-stage ventilator-compatible nitric
oxide product AirNOvent. For more information please visit
www.circassia.com.
Forward-looking statements
This press release contains certain projections and other
forward-looking statements with respect to the financial condition,
results of operations, businesses and prospects of Circassia. The
use of terms such as "may", "will", "should", "expect",
"anticipate", "project", "estimate", "intend", "continue", "target"
or "believe" and similar expressions (or the negatives thereof) are
generally intended to identify forward-looking statements. These
statements are based on current expectations and involve risk and
uncertainty because they relate to events and depend upon
circumstances that may or may not occur in the future. There are a
number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these
forward-looking statements. Any of the assumptions underlying these
forward-looking statements could prove inaccurate or incorrect and
therefore any results contemplated in the forward-looking
statements may not actually be achieved. Nothing contained in this
press release should be construed as a profit forecast or profit
estimate. Investors or other recipients are cautioned not to place
undue reliance on any forward-looking statements contained herein.
Circassia undertakes no obligation to update or revise (publicly or
otherwise) any forward-looking statement, whether as a result of
new information, future events or other circumstances.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCPGUQAWUPBGAB
(END) Dow Jones Newswires
March 29, 2019 11:58 ET (15:58 GMT)
Circassia (LSE:CIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Circassia (LSE:CIR)
Historical Stock Chart
From Apr 2023 to Apr 2024